^
    Back
    Association details:
    Biomarker:ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    The NCCN NSCLC Panel recommends crizotinib, entrectinib, or certinib (all are category 2A) as first-line therapy options for patients with ROS1-positive metastatic NSCLC...
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    AACR-II 2020
    Title:

    Abstract 741: Molecular and clinicopathological characteristics of Chinese non-small cell lung cancers with ROS1 gene fusions identified by next-generation sequencing

    Published date:
    05/15/2020
    Excerpt:
    Crizotinib has demonstrated robust response in treating ROS1-rearranged NSCLC, particularly in non-CD74 ROS1-positive patients.
    DOI:
    10.1158/1538-7445.AM2020-741
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Next-Generation Sequencing (NGS) for the Study of the Mechanism of Crizotinib Resistance in Patients with ROS1 Positive Non-Small Cell Lung Cancer (NSCLC).

    Excerpt:
    ...Ros1 fusion was detected by fish, PCR or NGS; 4. ...
    Trial ID:
    ChiCTR2000034441
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

    Excerpt:
    ...CT/MRI scans will be performed to evaluate the efficacy of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 fusion genes (primary outcome measure: objective response rate (ORR) according to RECIST v.1.1)`Objective Response Rate (ORR); evaluation criteria: investigator assessed RECIST v.1.1 analysis...
    Trial ID:
    EUCROSS
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2021
    Title:

    P45.14 - Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China

    Published date:
    08/18/2021
    Excerpt:
    A total of 55 patients were included in the study, of which 36 with ALK fusion, and 13 with ROS1 fusion....the ORR of crizotinib was 53% with a median PFS of 12 months (range: 1–102 months)...confirmed the therapeutic benefit of crizotinib in ALK/ROS-1fusion-positive advanced NSCLC, and also in NSCLC with MET ex14 mutation. Our data showed crizotinib is tolerable and effective, which is comparable with literature report.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Targeted Oncology
    Title:

    Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis

    Published date:
    08/31/2020
    Excerpt:
    The median PFS was 5.2 months, and median OS was 12.7 months….Our study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC with ROS1 or MET genetic alterations. Crizotinib had remarkable effects on advanced NSCLC with ROS1 fusion, as previously reported.
    DOI:
    10.1007/s11523-020-00745-7
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer

    Published date:
    10/15/2018
    Excerpt:
    Among 22 patients with ROS1-rearranged NSCLC, 20 patients were diagnosed at stage IV, and 19 patients received crizotinib treatment....It was shown that NSCLC patients with exclusive ROS1 rearrangement had a longer PFS than those carrying concomitant mutations (15.5 vs 8.5 months, P=0.0213).
    DOI:
    10.2147/OTT.S176273